Interventional Glaucoma

Common devices differ in hardware, analysis, and display of data

Applying a cautious approach can increase the chance for successful outcomes

Lipid regulation within primary cilia may prove to be a solution for patients

Some finesse may go a long way for physicians to ensure best possible result for patients

Secure closure of the scleral flap a key to avoiding early hypotony

Postoperative complications can have multiple causes and preventative measures

Selective laser trabeculoplasty (SLT) should be offered to patients diagnosed with open-angle glaucoma as a first-line therapy.

Here's the latest innovations at Neurotech Pharmaceuticals, Inc. 

Selective laser trabeculoplasty (SLT) could be an affordable option for glaucoma management, according to Nathan Radcliffe, MD. 

E. Randy Craven, MD, shares results from a phase 1/2 study involving an intracameral bimatoprost sustained-release implant. 

Test your knowledge on MIGS procedures

Differentiating across categories instrumental to establishing accurate value

Surgeons can anticipate flurry of product releases that will drive innovation

Surgeon sheds light on his experiences with variety of innovative surgery options

Project involves development of patient-reported outcome measure

CPC for glaucoma requires special finesse for surgery

Treatment options expand for patients along continuum of mild-to-severe disease

Surgical strategies can minimize risk by selecting appropriate patient, optimizing intraoperative view

The registry provides real-world evidence of safety, and durable efficacy of a glaucoma surgery device.  

Eye drops, drug-delivery system innovations aim to improve outcomes, adherence

If you find yourself waffling back and forth on private equity, Ruth D. Williams, MD, has some guidance tips to make the decision easier. 

Janey L. Wiggs, MD, PhD, shares the key points from her presentation.

Ellie Chabi, MD, Therapeutic Area Head for Glaucoma & Neuroprotection and Lead for Artificial Intelligence Programs within Global Biomedical Science for Santen, provides an update on its glaucoma pipeline.